DENTSPLY SIRONA Inc (NASDAQ:XRAY) issued an update on its FY17 earnings guidance on Tuesday morning. The company provided EPS guidance of $2.80-2.90 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.85.
DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings data on Tuesday, May 9th. The medical instruments supplier reported $0.49 earnings per share for the quarter, missing the consensus estimate of $0.50 by $0.01. The company had revenue of $900.50 million during the quarter, compared to analyst estimates of $916.55 million. DENTSPLY SIRONA had a net margin of 11.15% and a return on equity of 8.04%. The company’s revenue was up 16.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.69 EPS.
Several research firms have weighed in on XRAY. Zacks Investment Research upgraded shares of DENTSPLY SIRONA from a sell rating to a hold rating and set a $71.00 price objective for the company in a research report on Tuesday, May 2nd. Barrington Research cut shares of DENTSPLY SIRONA from an outperform rating to a market perform rating in a research report on Tuesday, February 21st. Stifel Nicolaus raised shares of DENTSPLY SIRONA from a hold rating to a buy rating and raised their target price for the company from $62.00 to $70.00 in a research note on Monday, February 13th. Finally, Jefferies Group LLC reduced their target price on shares of DENTSPLY SIRONA from $70.00 to $68.00 and set a buy rating on the stock in a research note on Monday, January 23rd. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $68.11.
In related news, insider Bret W. Wise sold 146,900 shares of DENTSPLY SIRONA stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $64.17, for a total transaction of $9,426,573.00. Following the transaction, the insider now owns 142,121 shares of the company’s stock, valued at approximately $9,119,904.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Christopher T. Clark sold 89,700 shares of DENTSPLY SIRONA stock in a transaction that occurred on Friday, April 7th. The stock was sold at an average price of $62.67, for a total transaction of $5,621,499.00. Following the transaction, the chief executive officer now directly owns 112,067 shares in the company, valued at approximately $7,023,238.89. The disclosure for this sale can be found here. Insiders sold a total of 314,141 shares of company stock worth $19,958,079 in the last ninety days. Insiders own 2.20% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “DENTSPLY SIRONA Inc (XRAY) Updates FY17 Earnings Guidance” was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.chaffeybreeze.com/2017/05/20/dentsply-sirona-inc-xray-issues-fy17-earnings-guidance-updated.html.
DENTSPLY SIRONA Company Profile
DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.
Receive News & Ratings for DENTSPLY SIRONA Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc and related companies with MarketBeat.com's FREE daily email newsletter.